Outcomes of COVID-19 patients undergoing extracorporeal membrane oxygenation: A systematic review and meta-Analysis.

IF 1.1 4区医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS

Perfusion-Uk Pub Date : 2025-01-01 Epub Date: 2023-12-29 DOI:10.1177/02676591231224645

Shouliang Jiang, Ping Yan, Zhongyang Ma, Juan Liang, Yong Hu, Jun Tang

{"title":"Outcomes of COVID-19 patients undergoing extracorporeal membrane oxygenation: A systematic review and meta-Analysis.","authors":"Shouliang Jiang, Ping Yan, Zhongyang Ma, Juan Liang, Yong Hu, Jun Tang","doi":"10.1177/02676591231224645","DOIUrl":null,"url":null,"abstract":"Background: The Coronavirus Disease 2019 (COVID-19) pandemic has been ongoing for over 3 years, during which numerous clinical and experimental studies have been conducted. The objective of this systematic review and meta-analysis was to assess the survival probability and complications of COVID-19 patients receiving extracorporeal membrane oxygenation (ECMO).Methods: We searched the databases by using Population-Intervention-Comparison-Outcome-Study Design (PICOS). We conducted a search of the PubMed, Web of Science, and EMBASE databases to retrieve studies published until December 10, 2022. A random-effects meta-analysis, subgroup analysis, and assessed the studies using the Newcastle-Ottawa Scale score. The results were presented as pooled morbidity with 95% confidence intervals.Results: The study was conducted on 19 studies that enrolled a total of 1494 patients, and the results showed a pooled survival probability of 66.0%. The pooled morbidity for intracranial hemorrhage was 8.7%, intracranial thrombosis 7.0%, pneumothorax 9.0%, pulmonary embolism 11.0%, pulmonary hemorrhage 9.0%, heart failure 14.0%, liver failure 13.0%, renal injury 44.0%, gastrointestinal hemorrhage 6.0%, gastrointestinal ischemia 6.0% and venous thrombosis 31.0%.Conclusion: This systematic review and meta-analysis of observational studies focused on the survival probability and complications of COVID-19 patients undergoing ECMO, which are significant in evaluating the use of ECMO in COVID-19 patients and provide a basis for further research.Trial registration: Our study was registered on PROSPERO with registration number CRD42022382555.","PeriodicalId":49707,"journal":{"name":"Perfusion-Uk","volume":" ","pages":"36-48"},"PeriodicalIF":1.1000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Perfusion-Uk","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/02676591231224645","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/29 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The Coronavirus Disease 2019 (COVID-19) pandemic has been ongoing for over 3 years, during which numerous clinical and experimental studies have been conducted. The objective of this systematic review and meta-analysis was to assess the survival probability and complications of COVID-19 patients receiving extracorporeal membrane oxygenation (ECMO).

Methods: We searched the databases by using Population-Intervention-Comparison-Outcome-Study Design (PICOS). We conducted a search of the PubMed, Web of Science, and EMBASE databases to retrieve studies published until December 10, 2022. A random-effects meta-analysis, subgroup analysis, and assessed the studies using the Newcastle-Ottawa Scale score. The results were presented as pooled morbidity with 95% confidence intervals.

Results: The study was conducted on 19 studies that enrolled a total of 1494 patients, and the results showed a pooled survival probability of 66.0%. The pooled morbidity for intracranial hemorrhage was 8.7%, intracranial thrombosis 7.0%, pneumothorax 9.0%, pulmonary embolism 11.0%, pulmonary hemorrhage 9.0%, heart failure 14.0%, liver failure 13.0%, renal injury 44.0%, gastrointestinal hemorrhage 6.0%, gastrointestinal ischemia 6.0% and venous thrombosis 31.0%.

Conclusion: This systematic review and meta-analysis of observational studies focused on the survival probability and complications of COVID-19 patients undergoing ECMO, which are significant in evaluating the use of ECMO in COVID-19 patients and provide a basis for further research.

Trial registration: Our study was registered on PROSPERO with registration number CRD42022382555.

查看原文本刊更多论文

接受体外膜肺氧合治疗的 COVID-19 患者的疗效：系统回顾与元分析。

背景：冠状病毒病 2019（COVID-19）大流行已持续 3 年多，期间进行了大量临床和实验研究。本系统综述和荟萃分析旨在评估接受体外膜肺氧合（ECMO）治疗的 COVID-19 患者的生存概率和并发症：方法：我们使用 "人群-干预-比较-结果-研究设计"（PICOS）对数据库进行了检索。我们在 PubMed、Web of Science 和 EMBASE 数据库中检索了截至 2022 年 12 月 10 日发表的研究。我们进行了随机效应荟萃分析、亚组分析，并使用纽卡斯尔-渥太华量表评分对研究进行了评估。结果以汇总发病率和 95% 置信区间的形式呈现：该研究对 19 项研究进行了分析，共招募了 1494 名患者，结果显示总生存率为 66.0%。颅内出血的集合发病率为 8.7%，颅内血栓形成为 7.0%，气胸为 9.0%，肺栓塞为 11.0%，肺出血为 9.0%，心力衰竭为 14.0%，肝功能衰竭为 13.0%，肾损伤为 44.0%，胃肠道出血为 6.0%，胃肠道缺血为 6.0%，静脉血栓形成为 31.0%：这项观察性研究的系统回顾和荟萃分析关注了接受 ECMO 的 COVID-19 患者的生存概率和并发症，对评估 COVID-19 患者使用 ECMO 有重要意义，并为进一步研究提供了依据：我们的研究已在 PROSPERO 注册，注册号为 CRD42022382555。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Perfusion-Uk 医学-外周血管病

CiteScore

3.00

自引率

8.30%

发文量

203

审稿时长

6-12 weeks

期刊介绍： Perfusion is an ISI-ranked, peer-reviewed scholarly journal, which provides current information on all aspects of perfusion, oxygenation and biocompatibility and their use in modern cardiac surgery. The journal is at the forefront of international research and development and presents an appropriately multidisciplinary approach to perfusion science.